← Back to Search

Nonsteroidal Anti-Inflammatory Drug

Ketorolac for Cataracts

Phase < 1
Recruiting
Led By Eric Donnenfeld, MD
Research Sponsored by DHS Consulting
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Undergoing cataract surgery immediately followed by pars plana vitrectomy
Diagnosed preoperatively with a structural pathology requiring vitrectomy (e.g., epiretinal membrane, macular hole, and symptomatic vitreous floaters)
Must not have
Patients undergoing cataract surgery or pars plana vitrectomy alone (not a combined procedure)
Age < 18
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the day of surgery
Awards & highlights

Summary

This trial is studying the levels of Ketorolac in eye samples from patients having cataract and vitrectomy surgeries with or without a specific eye medication called OMIDRIA. Some patients will

Who is the study for?
This trial is for patients who are scheduled to undergo combined cataract and pars plana vitrectomy surgeries. Specific eligibility criteria were not provided, so it's important to contact the study organizers for detailed requirements.
What is being tested?
The trial is testing Ketorolac levels in eye fluids during cataract/vitrectomy surgeries. One group will receive OMIDRIA (phenylephrine/ketorolac mix) inside the eye, while another gets topical ketorolac drops before surgery.
What are the potential side effects?
Possible side effects may include irritation or discomfort in the eye where Ketorolac is applied, potential allergic reactions, and temporary vision problems post-surgery.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am having cataract surgery followed by a specific eye surgery.
Select...
I have been diagnosed with a condition needing vitrectomy surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am having cataract surgery or a vitrectomy but not both at the same time.
Select...
I am under 18 years old.
Select...
I have had a vitrectomy.
Select...
I experienced complications during my cataract surgery.
Select...
I have a tear in the back part of my eye's lens capsule.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the day of surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and the day of surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Concentration of ketorolac in the vitreous humor

Trial Design

2Treatment groups
Active Control
Group I: OMIDRIAActive Control1 Intervention
OMIDRIA is a combination product containing 10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac in a single-patient-use vial. Once the 4mL of OMIDRIA is diluted in 500 mL of ophthalmic irrigation solution, the resulting solution is intended to be used as needed during cataract surgery or intraocular lens replacement.
Group II: Topical KetorolacActive Control1 Intervention
Topical ketorolac tromethamine 0.5% is a nonsteroidal anti-inflammatory drug. It is FDA-approved for the treatment of inflammation following cataract surgery and relief of ocular itching due to seasonal allergic conjunctivitis.

Find a Location

Who is running the clinical trial?

DHS ConsultingLead Sponsor
Eric Donnenfeld, MDPrincipal InvestigatorOphthalmic Consultants of Long Island
5 Previous Clinical Trials
306 Total Patients Enrolled
3 Trials studying Cataract
244 Patients Enrolled for Cataract
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top